Sort   by:  
 Page size 
UnknownPhase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
Not available
S-EPMC5321073 | biostudies-literature
UnknownBRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Not available
S-EPMC3413277 | biostudies-literature
UnknownOlaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Not available
S-EPMC6057749 | biostudies-literature
UnknownBibliometric analysis of hotspots and frontiers in cancer-related fatigue among ovarian cancer survivors.
Not available
S-EPMC9499248 | biostudies-literature
UnknownImatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Not available
S-EPMC4878082 | biostudies-literature
UnknownPatient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
Not available
S-EPMC4876313 | biostudies-literature
UnknownDevelopment of an Injectable, ECM-Derivative Embolic for the Treatment of Cerebral Saccular Aneurysms.
Not available
S-EPMC11323012 | biostudies-literature
UnknownRas pathway inhibition prevents neovascularization by repressing endothelial cell sprouting.
Not available
S-EPMC3809796 | biostudies-literature
UnknownVEGF regulates local inhibitory complement proteins in the eye and kidney.
Not available
S-EPMC5199702 | biostudies-literature
UnknownAnthrax lethal factor inhibition.
Not available
S-EPMC1138260 | biostudies-literature
Sort   by:  
 Page size